Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 41, Issue 8, 2008, Pages 749-751

  Hill, Q A ^a   Hill, A ^b   Collyns, T A ^a   Pearce, R M ^c   Cook, G ^d  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c BSBMT   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; MELPHALAN; METHOTREXATE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADENOVIRUS; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; CD4 CD8 RATIO; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG HALF LIFE; DRUG TREATMENT FAILURE; HODGKIN DISEASE; HUMAN; LETTER; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; SHORT COURSE THERAPY; SIDE EFFECT; T CELL DEPLETION; VIRUS INFECTION; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 42549169353     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705974     Document Type: Letter

References (10)

1. Perez-Simon JA, Kottaridis PD, Martin R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
2. Bainton RD, Byrne JL, Davy BJ, Russell NH. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002; 100: 3843-3844.
3. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261-267.
4. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 494-406.
5. Maury S, Mary JY, Rabian C, Schwarzinger M, Toubert A, Scieux C et al Prolonged immune deficiency following allogeneic stem cell transplantation: Risk factors and complications in adult patients. Br J Haematol 2001; 115: 630-641.
6. Kumar S, Chen MG, Gastineau DA, Gentz MA, Inwards DJ, Lacy MQ et al Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001; 28: 951-956.
7. Kumar S, Chen MG, Gastineau.DA, Gertz MA, Inwards DJ, Lacy MQ et al Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 2003; 17: 1865-1870.
8. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid, leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-3486.
9. Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation ds predictive for treatment outcome. Transplantation 2002; 14 1551-1559.
10. Avivi I, Chakrabarti S, Milligan DW, Waldmarm H, Hale G, Osman H et al. Incidence and outcomd of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10: 186-194.